From the Wires
Therapeutic Area Partnerships Features Next Generation of Oncology Treatments
New Wave of Newer Classes Will Be Discussed by Experts at Campbell Alliance
By: Marketwired .
Nov. 19, 2012 12:09 PM
BRIDGEWATER, NJ -- (Marketwire) -- 11/19/12 -- Next week Elsevier Business Intelligence will host the 7th Annual Therapeutic Area Partnerships (TAP) at The Westin Copley Place in Boston on Nov. 28-30, 2012. TAP is the most efficient partnering meeting for biopharmaceutical companies and executives seeking to understand, within their therapeutic area portfolio, the strategic outlook for new products in development, alliance opportunities, and current industry pipeline needs and future projections.
One of the six therapeutic areas featured at the conference, oncology remains by far the largest and most active deal-making space in the biopharmaceutical industry. While many new drugs will reach the market in the next few years, existing blockbusters and other widely used agents will soon go generic, potentially impacting reimbursement and uptake for novel medications. Emerging diagnostic biomarkers, immunotherapies and conjugated biological therapies have the potential to transform the way patients are treated. The fast-changing oncology landscape and its implications for the industry will be the subject of a roundtable of oncology business development leaders from four major global pharmaceutical firms guided by an expert team from Campbell Alliance, an industry leader in biopharmaceutical and medical technology consulting and part of inVentiv Health.
The oncology-specific segments of TAP include a panel discussion and presentation of the Top Projects to Watch. The panel, including executives from AstraZeneca, Genentech, EMD Serono and Sanofi, will give attendees actionable intelligence on the trends, hurdles and opportunities that will shape the future of oncology drug development, alliances, and commercialization.
The Top Projects to Watch in oncology were hand-picked by the Campbell Alliance team based on their likelihood of success as future products. The companies confirmed to present their oncology projects this year are:
Apogenix GmbH: (Apocept) APG101
"The next decade in oncology will see newer classes of agents added to the treatment armamentarium," said Guru Muralimohan, engagement manager at Campbell Alliance. "Cytotoxics will become smarter and more targeted. Immunotherapies will produce a new wave of blockbusters as they leverage the human body's own immune system to help combat cancer. And, next generation agents targeting cancer cell metabolism will have the potential for disruptive change in the oncology treatment paradigm."
"These ten assets represent the leading edge of this sea change in oncology, and were chosen through an exhaustive process that took into account a variety of factors," added Jonathan Betts, Engagement Manager at Campbell Alliance. Such factors included what key opinion leaders have defined as the most promising mechanistic approaches and emerging trends based on Campbell Alliance's 2012 Dealmakers' Intentions Survey as well as the firm's understanding of areas of high current licensing activity within oncology and knowledge gained through assisting multiple companies develop oncology strategies.
Both Muralimohan and Betts will co-present the oncology Top Projects to Watch.
TAP is a one-of-a-kind opportunity to assess some of the most promising drugs in development and available for partnering in Oncology, Cardiovascular/Metabolic Diseases, Neuroscience, Infectious Diseases, Autoimmune/Anti-Inflammatory Diseases, and Hot Space. Attracting the highest concentration of senior-level biotechnology and pharmaceuticals executives, TAP has come to be regarded as one the most productive, results-oriented deal-making conferences in the industry. For more information, or to register for this event, visit www.tapartnerships.com.
About Elsevier Business Intelligence
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Latest Cloud Developer Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week